2022 the Japanese Society of Medical Oncology Annual Meeting

Session information

Mini-Oral Session

[MO32] Mini-Oral Session 32 Clinical Trial Facilitation Program 2
【E】

Sat. Feb 19, 2022 9:10 AM - 10:00 AM Room 3 (Annex 2, 1F, Kyoto International Conference Center)

Chair:Wataru Okamoto(Cancer Treatment Center, Hiroshima University Hospital),Masami Kawahara(School of Pharmacy, Aichi Gakuin University)

Phichai Chansriwong1, Jitprapa Konmun1, Suwannee Sirilerttrakul2, Patamaporn Tangteerakoon4, Sineenuch Ckumdee2, Buasorn Wetchapan2, Sasiphat Khudamkreng2, Kedsarin Pinrarot2, Aujchayaporn Rattanaphom2, Teeraporn Klinumporn2, Siraprapa Kritongsuk2, Noppakan Wannakansophon3, Yaowarat Chantraporn3, Pinyo Utthiya3, Noppadon Kongsuphon4, Pimchanok Tuitemwong1,5, Nintita Sripaiboonkij Thokanit5 (1.Division of Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 2.Department of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., 3.Department of Nursing, Somdech Phra Debaratana Medical Center Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 4.Chemotherapy Pharmacy Service, Compounding Unit, Department of Pharmacy, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 5.Ramathibodi Comprehensive Cancer Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University.)

Yi-Hsin Yang1, Chen-Hao Wu1, Nai-Jung Chiang1, Yan-Shen Shan2, Li-Yuan Bai4, Chung-Pin Li5, Jen-Shi Chen6, Li-Tzong Chen1,3 (1.National Institute of Cancer Research, National Health Research Institutes, Taiwan, 2.National Cheng Kung University, Taiwan, 3.Kaohsiung Medical University Hospital, Taiwan, 4.China Medical University Hospital, Taiwan, 5.Taipei Veterans General Hospital, Taiwan, 6.Linkou Chang Gung Memorial Hospital, Taiwan)

Shosuke Kita1,2, Noguchi Emi1,2, Okita Natsuko1,3, Ushirozawa Nobuko1, Shibata Taro1,4, Yonemori Kan1,2 (1.Office for Advanced Medical Care Evaluation & Health Technology Assessment, National Cancer Center, 2.Department of Medical Oncology, National Cancer Center Hospital, 3.Research Management Division, Clinical Research Support Office, National Cancer Center Hospital, 4.Biostatistics Division, Center for Research Administration and Support, National Cancer Center)

Katsutoshi Oda1, Hidenori Kage1, Manabu Muto2, Tsuchihara Katsuya3, Okita Natsuko4, Okuma Yusuki5, Kikuchi Junko6, Hidekazu Shirota7, Hayashi Hideyuki8, Toshio Kokuryo9, Sakai Daisuke10, Mariko Kochi11, Makoto Kubo12, Hirotsugu Kenmotsu13, Ushiku Aya1,14, Masahiko Tanabe1,15, Tetsuo Ushiku1,14, Kiyoshi Miyagawa1,16, Yasuyuki Seto17 (1.Department of Clinical Genomics, The University of Tokyo Hospital, 2.Department of Therapeutic Oncology, Kyoto University, 3.Division of Translational Informatics, National Cancer Center Hospital East, 4.Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 5.Department of Thoracic Oncology, National Cancer Center Hospital, 6.Internal Medicine I, Hokkaido University, 7.Department of Clinical Oncology, Tohoku University Hospital, 8.Genomics Unit, Keio Cancer Center, Keio University, 9.Division of Surgical Oncology, Department of Surgery, Nagoya University, 10.Center for Cancer Genomics and Personalized Medicine, Osaka University, 11.Department of Clinical Genetics and Genomic Medicine, Okayama University, 12.Department of Surgery and Oncology, Kyushu University, 13.Division of Thoracic Oncology, Shizuoka Cancer Center, 14.Department of Pathology, The University of Tokyo, 15.Department of Breast and Endocrine Surgery, The University of Tokyo, 16.Center for Disease Biology and Integrative Medicine, The University of Tokyo, 17.Gastrointestinal Surgery, The University of Tokyo)